CRISPR Therapeutics AG CRSP
5 trading plans running, 10 Form 144 notices for $15.9M
10-Q, 10-K and Form 144What CRSP's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Jun 11, 2024 to May 31, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in |
|---|---|---|---|
| Raju Prasad Chief Financial Officer |
Adopted 10b5-1 plan | Jun 9, 2026 | 10-Q Aug 3, 2026 |
| James R. Kasinger General Counsel and Secretary |
Adopted 10b5-1 plan | May 6, 2026 | 10-Q Aug 3, 2026 |
| Naimish Patel M.D. (Chief Medical Officer) |
Adopted 10b5-1 plan | Dec 16, 2025 | 10-K Feb 12, 2026 |
| Simeon J. George M.D. (Member of the Board of Directors) |
Adopted 10b5-1 plan | Dec 12, 2025 | 10-K Feb 12, 2026 |
| Katherine A. High M.D. (Member of the Board of Directors) |
Adopted 10b5-1 plan | Nov 14, 2025 | 10-K Feb 12, 2026 |
| Samarth Kulkarni Chief Executive Officer |
Ended 10b5-1 plan | Aug 27, 2025 | 10-Q Nov 10, 2025 |
| Raju Prasad, Chief Financial Officer |
Adopted 10b5-1 plan | Aug 18, 2025 | 10-Q Nov 10, 2025 |
| James R. Kasinger General Counsel |
Adopted 10b5-1 plan | Aug 6, 2025 | 10-Q Nov 10, 2025 |
| Samarth Kulkarni Chief Executive Officer |
Adopted 10b5-1 plan | Jun 10, 2025 | 10-Q Aug 4, 2025 |
| Samarth Kulkarni Chief Executive Officer |
Adopted 10b5-1 plan | Jun 13, 2024 | 10-Q Aug 5, 2024 |
| Raju Prasad Chief Financial Officer |
Adopted 10b5-1 plan | Jun 11, 2024 | 10-Q Aug 5, 2024 |
| Jim Kasinger General Counsel and Secretary |
Adopted 10b5-1 plan | Mar 4, 2024 | 10-Q May 8, 2024 |
| Dr. Katherine High | Adopted 10b5-1 plan | Dec 6, 2023 | 10-K Feb 21, 2024 |
| Dr. Samarth Kulkarni Chief Executive Officer and Chairman of our Board of Directors |
Adopted 10b5-1 plan | Sep 15, 2023 | 10-Q Nov 6, 2023 |
| Dr. Phuong Khanh Morrow Chief Medical Officer |
Adopted 10b5-1 plan | Sep 7, 2023 | 10-Q Nov 6, 2023 |
Show the other 7 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 6, 2026 | RAJU PRASAD Officer |
79,393 | $4.0M |
| Oct 14, 2026 | SIMEON GEORGE Director |
14,514 | $720K |
| Oct 6, 2026 | JAMES KASINGER Officer |
1,990 | $119K |
| Sep 22, 2026 | JAMES KASINGER Officer |
10,400 | $626K |
| Sep 17, 2026 | ALI BEHBAHANI Director |
13,679 | $781K |
| Jan 22, 2026 | Samarth Kulkarni Officer |
60,000 | $3.6M |
| Jan 22, 2026 | RAJU PRASAD Officer |
34,972 | $2.1M |
| Jan 20, 2026 | Samarth Kulkarni Officer |
30,000 | $1.6M |
| Jan 6, 2026 | RAJU PRASAD Officer |
29,700 | $1.8M |
| Dec 22, 2025 | RAJU PRASAD Officer |
10,000 | $560K |
Show the other 2 notices
From the Form 144 XML filed with the SEC, since Dec 22, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CRSP/export.csv") into a cell.